GEVO vs BYFC vs CARV vs VERO

For growth investors, Gevo, Inc.

(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus -15. 1% for Venus Concept Inc. (VERO). Analysts rate Gevo, Inc. (GEVO) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Broadway Financial Corporation (BYFC) delivered a total return of -33.

2%, compared to -99. 9% for Venus Concept Inc. (VERO). Over 10 years, the gap is even starker: BYFC returned -37. 6% versus VERO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Broadway Financial Corporation (BYFC) is the lower-risk stock at 0.

02β versus Gevo, Inc. 's 1. 64β — meaning GEVO is approximately 6504% more volatile than BYFC relative to the S&P 500. On balance sheet safety, Gevo, Inc. (GEVO) carries a lower debt/equity ratio of 36% versus 15% for Venus Concept Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Gevo, Inc.

(GEVO) is pulling ahead at 849. 3% versus -15. 1% for Venus Concept Inc. (VERO). On earnings-per-share growth, the picture is similar: Gevo, Inc. grew EPS 58. 8% year-over-year, compared to -81. 8% for Broadway Financial Corporation. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Gevo, Inc.

(GEVO) is the more profitable company, earning -21. 1% net margin versus -72. 5% for Venus Concept Inc. — meaning it keeps -21. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GEVO leads at -11. 7% versus -41. 9% for VERO. At the gross margin level — before operating expenses — VERO leads at 68. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, BYFC (3.

5% yield) pays a dividend. GEVO, CARV, VERO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Broadway Financial Corporation (BYFC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

02), 3. 5% yield). Gevo, Inc. (GEVO) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BYFC: -37. 6%, GEVO: -98. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (GEVO (Basic Materials) and BYFC (Financial Services) and CARV (Financial Services) and VERO (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GEVO is a small-cap high-growth stock; BYFC is a small-cap income-oriented stock; CARV is a small-cap quality compounder stock; VERO is a small-cap quality compounder stock. BYFC pays a dividend while GEVO, CARV, VERO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.